KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

Core Insights - KalVista Pharmaceuticals, Inc. reported a quarterly loss of $1.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.91, marking an earnings surprise of -23.08% [1] - The company generated revenues of $1.43 million for the quarter ended July 2025, missing the Zacks Consensus Estimate by 20.91%, compared to zero revenues a year ago [2] - The stock has increased approximately 81.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 11.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.89 on revenues of $5.46 million, and for the current fiscal year, it is -$3.06 on revenues of $30.02 million [7] - The estimate revisions trend for KalVista Pharmaceuticals was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which KalVista Pharmaceuticals belongs, is currently in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]